Radiotherapy in Early Stage Hodgkin's Disease

P. L. Zinzani Institutes of Hematology “L. e A. Seràgnoli” and Radiotherapy “L. Galvani,” University of Bologna

E. Barbieri Institutes of Hematology “L. e A. Seràgnoli” and Radiotherapy “L. Galvani,” University of Bologna

F. Gherlinzoni Institutes of Hematology “L. e A. Seràgnoli” and Radiotherapy “L. Galvani,” University of Bologna

G. Frezza Institutes of Hematology “L. e A. Seràgnoli” and Radiotherapy “L. Galvani,” University of Bologna

P. Mazza Hematology Department, Ospedale Civile SS. Annunziata, Taranto, Italy

A. Pica Institutes of Hematology “L. e A. Seràgnoli” and Radiotherapy “L. Galvani,” University of Bologna

I. Ammendolia Institutes of Hematology “L. e A. Seràgnoli” and Radiotherapy “L. Galvani,” University of Bologna

M. Bendandi Institutes of Hematology “L. e A. Seràgnoli” and Radiotherapy “L. Galvani,” University of Bologna

S. Neri Institutes of Hematology “L. e A. Seràgnoli” and Radiotherapy “L. Galvani,” University of Bologna

G. Miniaci Institutes of Hematology “L. e A. Seràgnoli” and Radiotherapy “L. Galvani,” University of Bologna

M. Fiacchini Institutes of Hematology “L. e A. Seràgnoli” and Radiotherapy “L. Galvani,” University of Bologna

L. Babini Institutes of Hematology “L. e A. Seràgnoli” and Radiotherapy “L. Galvani,” University of Bologna

S. Tura Institutes of Hematology “L. e A. Seràgnoli” and Radiotherapy “L. Galvani,” University of Bologna

show all

Abstract

Ninety-nine patients with “standard risk” Stage IA-IIA Hodgkin's disease observed between January 1983 and December 1990, received radiotherapy only. The complete response rate was 98% (97/99). Twenty-one patients (21%) relapsed, 17 of whom (81%) obtained a second complete remission. The projected 9-year overall survival and disease-free survival were 95% and 78%, respectively. In this study our goals were to reduce the irradiation volumes, to decrease the number of splenectomies performed at diagnosis, and to utilize radiotherapy alone in these patients. We were able to reduce the irradiation volumes in over 50% and 80% of the patients with disease in the upper torso and subdiaphragm, respectively. Furthermore, this therapeutic approach permitted us to reduce the acute and long-term toxic effects related to splenectomy and combined modality treatment.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Radiotherapy in Early Stage Hodgkin's Disease

Information for

Open access

Opportunities

Help and information

Radiotherapy in Early Stage Hodgkin's Disease

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature